Mephenoxalone

Mephenoxalone

SCHEMBL2175454

COc1ccccc1OCC1CNC(=O)O1.N

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.75
SYK P43405 9/20 0.58
ADRA2C P18825 1/20 0.54
LMNA P02545 2/20 0.53
MAOA P21397 1/20 0.53
SLC6A2 P23975 1/20 0.53
IRAK4 Q9NWZ3 2/20 0.53
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 1/20 0.47
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mephenoxalone SCHEMBL4621926 0.99 PKM (0.77) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL935967 0.99 PKM (0.77) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL5392 0.99 PKM (0.77) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL1969509 0.97 PKM (0.75) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL1061349 0.97 PKM (0.75) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL6098064 0.97 PKM (0.75) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL7938104 0.97 PKM (0.75) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL22472152 0.97 PKM (0.75) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL7117835 0.97 PKM (0.75) PKMSYKADRA2CLMNAMAOA
Mephenoxalone SCHEMBL6492968 0.96 PKM (0.73) PKMSYKADRA2CLMNAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024035618-A1 PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME LLC (US) 2024-02-15 WO disclosed
EP-2521723-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF Enantia, S.L. (ES) 2012-11-14 EP disclosed
US-20120283434-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF ENANTIA, S.L. (ES) 2012-11-08 US disclosed
WO-2011080341-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF ENANTIA, S.L. (ES) 2011-07-07 WO disclosed
US-7649015-B2 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. (US) 2010-01-19 US disclosed
US-7390825-B1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-24 US disclosed
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-19 US disclosed
US-20070265451-A1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2007-11-15 US disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 US disclosed
EP-1578723-A4 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF UNIV MICHIGAN STATE (US) 2006-11-02 EP disclosed
US-20020183371-A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation GORDEEV MIKHAIL F (US) 2002-12-05 US disclosed
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-31 US disclosed
US-6413981-B1 DRUG-RESISTANT GRAM POSITIVE AND GRAM NEGATIVE BACTERIA; PNEUMONIA; INFECTIONS OF UPPER AND LOWER RESPIRATORY TRACT, SKIN, SOFT TISSUE, BONES AND JOINTS ORTHO-MCNEIL PHARAMCEUTICAL, INC. 2002-07-02 US disclosed
EP-1206469-A1 ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES Ortho-McNeil Pharmaceutical, Inc. (US) 2002-05-22 EP disclosed
EP-0892792-B1 PROCESS TO PREPARE OXAZOLIDINONES UPJOHN CO (US) 2001-11-21 EP disclosed
WO-2001042242-A1 ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-06-14 WO disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 US disclosed
EP-1049682-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION Versicor, Inc. (US) 2000-11-08 EP disclosed
WO-1999037630-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION VERSICOR, INC. (US) 1999-07-29 WO disclosed
US-5422042-A Improved toughness and flexibility HUNTSMAN CORPORATION (US) 1995-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265451-A1 Process for the preparation of oxazolidinones and method of use thereof OXA1L, OTC, ODC1 PKM 725/4885SYK 184/4885ADRA2C 3645/4885
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods OXA1L, NDUFS3, CYCS PKM 974/4885SYK 1208/4885ADRA2C 3460/4885
US-20020183371-A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PAICS, CDK4, OXA1L PKM 147/4885SYK 56/4885ADRA2C 4178/4885
US-20120283434-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF F12, VKORC1, CYP2C9 PKM 2536/4885SYK 2616/4885ADRA2C 1232/4885
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF OXA1L, OGFOD1, CYP51A1 PKM 816/4885SYK 91/4885ADRA2C 3318/4885
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds PPA1, PNP, PPME1 PKM 880/4885SYK 4464/4885ADRA2C 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.